IBDEI11P ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37921,1,4,0)
 ;;=4^I63.50
 ;;^UTILITY(U,$J,358.3,37921,2)
 ;;=^5007343
 ;;^UTILITY(U,$J,358.3,37922,0)
 ;;=I82.91^^140^1883^7
 ;;^UTILITY(U,$J,358.3,37922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37922,1,3,0)
 ;;=3^Chronic Embolism/Thrombosis Unspec Vein
 ;;^UTILITY(U,$J,358.3,37922,1,4,0)
 ;;=4^I82.91
 ;;^UTILITY(U,$J,358.3,37922,2)
 ;;=^5007941
 ;;^UTILITY(U,$J,358.3,37923,0)
 ;;=I25.9^^140^1883^8
 ;;^UTILITY(U,$J,358.3,37923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37923,1,3,0)
 ;;=3^Chronic Ischemic Heart Disease,Unspec
 ;;^UTILITY(U,$J,358.3,37923,1,4,0)
 ;;=4^I25.9
 ;;^UTILITY(U,$J,358.3,37923,2)
 ;;=^5007144
 ;;^UTILITY(U,$J,358.3,37924,0)
 ;;=D68.9^^140^1883^9
 ;;^UTILITY(U,$J,358.3,37924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37924,1,3,0)
 ;;=3^Coagulation Defect,Unspec
 ;;^UTILITY(U,$J,358.3,37924,1,4,0)
 ;;=4^D68.9
 ;;^UTILITY(U,$J,358.3,37924,2)
 ;;=^5002364
 ;;^UTILITY(U,$J,358.3,37925,0)
 ;;=D68.8^^140^1883^10
 ;;^UTILITY(U,$J,358.3,37925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37925,1,3,0)
 ;;=3^Coagulation Defects,Other Spec
 ;;^UTILITY(U,$J,358.3,37925,1,4,0)
 ;;=4^D68.8
 ;;^UTILITY(U,$J,358.3,37925,2)
 ;;=^5002363
 ;;^UTILITY(U,$J,358.3,37926,0)
 ;;=D68.318^^140^1883^11
 ;;^UTILITY(U,$J,358.3,37926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37926,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
 ;;^UTILITY(U,$J,358.3,37926,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,37926,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,37927,0)
 ;;=Z79.01^^140^1883^12
 ;;^UTILITY(U,$J,358.3,37927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37927,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,37927,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,37927,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,37928,0)
 ;;=Z79.02^^140^1883^13
 ;;^UTILITY(U,$J,358.3,37928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37928,1,3,0)
 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,37928,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,37928,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,37929,0)
 ;;=D68.62^^140^1883^14
 ;;^UTILITY(U,$J,358.3,37929,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37929,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,37929,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,37929,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,37930,0)
 ;;=I73.9^^140^1883^15
 ;;^UTILITY(U,$J,358.3,37930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37930,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,37930,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,37930,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,37931,0)
 ;;=Z86.79^^140^1883^16
 ;;^UTILITY(U,$J,358.3,37931,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37931,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,37931,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,37931,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,37932,0)
 ;;=Z86.711^^140^1883^17
 ;;^UTILITY(U,$J,358.3,37932,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37932,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,37932,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,37932,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,37933,0)
 ;;=Z86.718^^140^1883^18
 ;;^UTILITY(U,$J,358.3,37933,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37933,1,3,0)
 ;;=3^Personal Hx of Venous Thrombosis/Embolism
 ;;^UTILITY(U,$J,358.3,37933,1,4,0)
 ;;=4^Z86.718
 ;;^UTILITY(U,$J,358.3,37933,2)
 ;;=^5063475
 ;;^UTILITY(U,$J,358.3,37934,0)
 ;;=Z95.2^^140^1883^19
 ;;^UTILITY(U,$J,358.3,37934,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37934,1,3,0)
 ;;=3^Presence of Prosthetic Heart Valve
 ;;^UTILITY(U,$J,358.3,37934,1,4,0)
 ;;=4^Z95.2
 ;;^UTILITY(U,$J,358.3,37934,2)
 ;;=^5063670
 ;;^UTILITY(U,$J,358.3,37935,0)
 ;;=D68.59^^140^1883^20
 ;;^UTILITY(U,$J,358.3,37935,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37935,1,3,0)
 ;;=3^Primary Thrombophilia
 ;;^UTILITY(U,$J,358.3,37935,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,37935,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,37936,0)
 ;;=I26.99^^140^1883^21
 ;;^UTILITY(U,$J,358.3,37936,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37936,1,3,0)
 ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
 ;;^UTILITY(U,$J,358.3,37936,1,4,0)
 ;;=4^I26.99
 ;;^UTILITY(U,$J,358.3,37936,2)
 ;;=^5007150
 ;;^UTILITY(U,$J,358.3,37937,0)
 ;;=I42.5^^140^1883^22
 ;;^UTILITY(U,$J,358.3,37937,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37937,1,3,0)
 ;;=3^Restrictive Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,37937,1,4,0)
 ;;=4^I42.5
 ;;^UTILITY(U,$J,358.3,37937,2)
 ;;=^5007196
 ;;^UTILITY(U,$J,358.3,37938,0)
 ;;=G45.9^^140^1883^24
 ;;^UTILITY(U,$J,358.3,37938,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37938,1,3,0)
 ;;=3^Transient Cerebral Ischemic Attack,Unspec
 ;;^UTILITY(U,$J,358.3,37938,1,4,0)
 ;;=4^G45.9
 ;;^UTILITY(U,$J,358.3,37938,2)
 ;;=^5003959
 ;;^UTILITY(U,$J,358.3,37939,0)
 ;;=99441^^141^1884^1^^^^1
 ;;^UTILITY(U,$J,358.3,37939,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37939,1,1,0)
 ;;=1^99441
 ;;^UTILITY(U,$J,358.3,37939,1,2,0)
 ;;=2^PHONE E/M 5-10 MIN
 ;;^UTILITY(U,$J,358.3,37940,0)
 ;;=99443^^141^1884^3^^^^1
 ;;^UTILITY(U,$J,358.3,37940,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37940,1,1,0)
 ;;=1^99443
 ;;^UTILITY(U,$J,358.3,37940,1,2,0)
 ;;=2^PHONE E/M 21-30 MIN
 ;;^UTILITY(U,$J,358.3,37941,0)
 ;;=99442^^141^1884^2^^^^1
 ;;^UTILITY(U,$J,358.3,37941,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37941,1,1,0)
 ;;=1^99442
 ;;^UTILITY(U,$J,358.3,37941,1,2,0)
 ;;=2^PHONE E/M 11-20 MIN
 ;;^UTILITY(U,$J,358.3,37942,0)
 ;;=98966^^141^1885^1^^^^1
 ;;^UTILITY(U,$J,358.3,37942,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37942,1,1,0)
 ;;=1^98966
 ;;^UTILITY(U,$J,358.3,37942,1,2,0)
 ;;=2^PHONE CALL BY HC PROF 5-10 MIN
 ;;^UTILITY(U,$J,358.3,37943,0)
 ;;=98967^^141^1885^2^^^^1
 ;;^UTILITY(U,$J,358.3,37943,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37943,1,1,0)
 ;;=1^98967
 ;;^UTILITY(U,$J,358.3,37943,1,2,0)
 ;;=2^PHONE CALL BY HC PROF 11-20 MIN
 ;;^UTILITY(U,$J,358.3,37944,0)
 ;;=98968^^141^1885^3^^^^1
 ;;^UTILITY(U,$J,358.3,37944,1,0)
 ;;=^358.31IA^2^2
 ;;^UTILITY(U,$J,358.3,37944,1,1,0)
 ;;=1^98968
 ;;^UTILITY(U,$J,358.3,37944,1,2,0)
 ;;=2^PHONE CALL BY HC PROF 21-30 MIN
 ;;^UTILITY(U,$J,358.3,37945,0)
 ;;=E13.9^^142^1886^10
 ;;^UTILITY(U,$J,358.3,37945,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37945,1,3,0)
 ;;=3^Diabetes Mellitus w/o Complications,Other Spec
 ;;^UTILITY(U,$J,358.3,37945,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,37945,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,37946,0)
 ;;=R93.8^^142^1886^2
 ;;^UTILITY(U,$J,358.3,37946,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37946,1,3,0)
 ;;=3^Abnormal Findings on Diagnostic Imaging of Body Structures
 ;;^UTILITY(U,$J,358.3,37946,1,4,0)
 ;;=4^R93.8
 ;;^UTILITY(U,$J,358.3,37946,2)
 ;;=^5019721
 ;;^UTILITY(U,$J,358.3,37947,0)
 ;;=R94.8^^142^1886^4
 ;;^UTILITY(U,$J,358.3,37947,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37947,1,3,0)
 ;;=3^Abnormal Results of Function Studies of Organs/Systems
 ;;^UTILITY(U,$J,358.3,37947,1,4,0)
 ;;=4^R94.8
 ;;^UTILITY(U,$J,358.3,37947,2)
 ;;=^5019745
 ;;^UTILITY(U,$J,358.3,37948,0)
 ;;=Z63.4^^142^1886^7
 ;;^UTILITY(U,$J,358.3,37948,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37948,1,3,0)
 ;;=3^Bereavement
 ;;^UTILITY(U,$J,358.3,37948,1,4,0)
 ;;=4^Z63.4
 ;;^UTILITY(U,$J,358.3,37948,2)
 ;;=^5063168
 ;;^UTILITY(U,$J,358.3,37949,0)
 ;;=Z45.2^^142^1886^5
 ;;^UTILITY(U,$J,358.3,37949,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37949,1,3,0)
 ;;=3^Adjustment & Management of VAD
 ;;^UTILITY(U,$J,358.3,37949,1,4,0)
 ;;=4^Z45.2
 ;;^UTILITY(U,$J,358.3,37949,2)
 ;;=^5062999
 ;;^UTILITY(U,$J,358.3,37950,0)
 ;;=Z76.0^^142^1886^18
 ;;^UTILITY(U,$J,358.3,37950,1,0)
 ;;=^358.31IA^4^2
